[68Ga]Ga-DOTANOC 非靶向摄取的解剖部位与病因系统图谱
非肿瘤性病因占 59.6%,恶性占 30.2%,良性肿瘤占 10.3%;腹部最常见,其次为胸部、头颈及骨肌。
要点
- 腹部非靶向摄取最易与神经内分泌肿瘤常见区域重叠,是主要判读难点
- 非肿瘤性病因占比近六成,遇见高摄取不应直接提示肿瘤性病变
- 识别这些摄取模式有助于提高诊断准确率并拓展其临床适应证
核心结论
- 腹部非靶向 [68Ga]Ga-DOTANOC 摄取是 PET/CT 判读的主要挑战,因其常与神经内分泌肿瘤好发区域重叠
- 识别基于解剖和病因的非靶向摄取模式可提升诊断准确性,并支持超出神经内分泌肿瘤和脑膜瘤之外的临床扩展应用
研究设计与样本
- 系统综述,检索 PubMed、Web of Science 和 Scopus 数据库,更新至 2025 年 5 月 31 日
- 三名作者独立筛选标题和摘要,依据纳入与排除标准选择文献
诊断标准与关键数值
- 非靶向 [68Ga]Ga-DOTANOC 摄取需经组织病理或随访证实与正常生物分布及原发性生长抑素受体表达疾病无关
- 非肿瘤性病因占 59.6%,恶性病因占 30.2%,良性肿瘤性病因占 10.3%
- 解剖分布频率为腹部 38%、胸部 21.6%、头颈部 18.1%、肌肉骨骼系统 13.1%、盆腔 9%
临床应用与阅片要点
- 阅片时应认识到腹部非靶向摄取与神经内分泌肿瘤典型区域高度重叠,避免误判为原发或转移灶
- 对非靶向高摄取灶应结合部位、形态及临床资料评估非肿瘤性、良性与恶性可能
- 出现非常规部位摄取时,可考虑扩大 [68Ga]Ga-DOTANOC PET 的诊断应用价值,而非一律视为假阳性
局限性
- 所报告的非靶向病灶均来源于文献,可能存在发表偏倚和病例选择性报告
- 不同研究之间缺乏统一的征象描述与判读标准,可能影响病因和解剖分布汇总的异质性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This systematic review describes the spectrum, distribution, and etiologies of non‑target [68Ga]Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-1-Nal³-octreotide ([68Ga]Ga‑DOTANOC)‑avid lesions proven by histopathology or follow‑up to be unrelated to normal biodistribution or the primary somatostatin receptor‑expressing disease.
METHODS: PubMed, Web of Science, and Scopus databases were utilized to conduct a systematic search and were updated until May 31, 2025. Three authors independently screened the titles and abstracts of the retrieved articles and selected the articles on the basis of the inclusion and exclusion criteria.
RESULTS: Seventy-six eligible studies encompassing 542 patients reported 799 non-target [68Ga]Ga-DOTANOC-avid findings. Nononcologic causes accounted for the majority (59.6%), with malignant oncologic and benign tumorous etiologies accounting for 30.2% and 10.3%, respectively. The abdomen was the most common anatomical site (38%), followed by the thorax (21.6%), head/neck (18.1%), and musculoskeletal system (13.1%), whereas pelvic involvement was least common (9%).
CONCLUSIONS: Abdominal non-target [68Ga]Ga-DOTANOC-avid findings represent a major interpretive challenge in [68Ga]Ga-DOTANOC PET/CT, as these findings often overlap with NET-predominant regions. Recognition of these patterns can increase diagnostic accuracy and support broader clinical integration of [68Ga]Ga-DOTANOC beyond its conventional utility.
ADVANCES IN KNOWLEDGE: This systematic review clarifies anatomy-based and etiology-based non-target findings that can be encountered in [68Ga]Ga-DOTANOC PET imaging. Non-target findings with [68Ga]Ga-DOTANOC, while challenging, may expand its use beyond NETs and meningiomas, opening new diagnostic avenues.
引用
- Al-Adhami, Abdlkadir, Abdlkadir, et al. First systematic mapping of non-target [68Ga]Ga-DOTANOC uptake across anatomical sites and etiologies. Br J Radiol. 2026. PMID: 42568138. doi:10.1093/bjr/tqag181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。